Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
Holding SAGE?
Track your performance easily
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.62 - $28.26
Previous Close$5.17
Volume871.04K
Average Volume (3M)720.36K
Market Cap
$316.27M
Enterprise Value-$242.61M
Total Cash (Recent Filing)$569.15M
Total Debt (Recent Filing)$10.27M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 19, 2025EPS Estimate
-$1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.58
Shares Outstanding61,173,263
10 Day Avg. Volume810,397
30 Day Avg. Volume720,355
Standard Deviation0.16
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.54
Price to Sales (P/S)2.82
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-9.43
Enterprise Value/Gross Profit-2.81
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$10.07Price Target Upside94.78% Upside
Rating ConsensusHold
Number of Analyst Covering18
SAGE Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market AdoptionZurzuvae is being used as a first-line treatment for PPD by the majority of prescribers, and it is included in treatment guidelines by the American College of Obstetricians and Gynecologists.
Product SalesZurzuvae achieved total 3Q24 sales of ~$22M, representing ~49% growth and ~20% ahead of consensus expectations.
Revenue PerformanceSAGE's total revenue in 3Q24 of $11.9M was higher than consensus of $10.8M.
Bears Say
Clinical TrialsPhase 2 DIMENSION trial evaluating dalzanemdor in cognitive impairment associated with Huntington’s disease did not meet the primary endpoint, and no statistically significant or clinically meaningful differences were seen on secondary endpoints.
Financial OutlookRemoval of dalzanemdor value lowers the price target to $9 from a prior $10, reflecting diminished expectations due to multiple clinical setbacks.
Strategic UncertaintyVisibility around how SAGE might put its $569 million in cash to work remains poor, raising concerns about strategic direction and potential impact on stock performance.
---
Ownership Overview
1.60% Insiders
22.21% Mutual Funds
27.50% Other Institutional Investors
32.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $4.62 and its highest was $28.26 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Feb 19, 2025 which is in 86 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Oct 29, 2024. The company reported -$1.53 earnings per share for the quarter, beating the consensus estimate of -$1.542 by $0.012.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.53.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 61,173,264 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.53 in its last earnings report, beating expectations of -$1.542. Following the earnings report the stock price went down -24.057%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 3M.
---
SAGE Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.07 (94.78% Upside)
$10.07 (94.78% Upside)
Hedge Fund Trend
Decreased
By 109.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.39%
12-Months-Change
Fundamentals
Return on Equity
-49.34%
Trailing 12-Months
Asset Growth
-34.46%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q3 2024
0:00 / 0:00
---
SAGE Stock 12 Month Forecast
Average Price Target
$10.07
▲(94.78% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+3.68%
reiterated a sell rating 5 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +3.68% per trade.
---